Cargando…

Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review

BACKGROUND: A shift in biochemical research towards drugs for rare diseases has created new challenges for the pharmaceutical industry, government regulators, health technology assessment agencies, and public and private payers. In this article, we aim to comprehensively review, characterize, identi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janoudi, Ghayath, Amegatse, William, McIntosh, Brendan, Sehgal, Chander, Richter, Trevor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134221/ https://www.ncbi.nlm.nih.gov/pubmed/27908281 http://dx.doi.org/10.1186/s13023-016-0539-3

Ejemplares similares

Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR
por: Richter, Trevor, et al.
Publicado: (2018)

Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations
por: Binder, Louise, et al.
Publicado: (2022)

Patients’ perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review
por: Berglas, Sarah, et al.
Publicado: (2016)

Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations
por: Jenei, Kristina, et al.
Publicado: (2023)

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
por: Lau, Catherine, et al.
Publicado: (2022)

Interactions of recommended COVID-19 drugs with commonly used psychotropics
por: Chatterjee, Seshadri Sekhar, et al.
Publicado: (2020)

Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand
por: McCormick, John I., et al.
Publicado: (2018)

Inpatient Z-drug use commonly exceeds safe dosing recommendations
por: Lee, Todd C., et al.
Publicado: (2017)

Bronchiolitis and asthma: Possible common pathogenetic pathways()
por: McIntosh, Kenneth
Publicado: (1976)

Human cytomegalovirus and transplantation: drug development and regulatory issues
por: McIntosh, Megan, et al.
Publicado: (2016)

Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis
por: Pham, Ba', et al.
Publicado: (2019)

Trends in Light and Temperature Sensitivity Recommendations among Licensed Biotechnology Drug Products
por: Kim, Jennifer J., et al.
Publicado: (2023)

Establishing a reasonable price for an orphan drug
por: Berdud, Mikel, et al.
Publicado: (2020)

Dose Recommendations for Common Drugs in Patients with Liver Cirrhosis: A Systematic Literature Review
por: Karsten Dafonte, Katharina, et al.
Publicado: (2023)

In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar
por: Bansal, Devendra, et al.
Publicado: (2004)

Do Case Reports and Case Series Generate Clinical Discoveries About Preeclampsia? A Systematic Review
por: Janoudi, Ghayath, et al.
Publicado: (2023)

Structured override reasons for drug-drug interaction alerts in electronic health records
por: Wright, Adam, et al.
Publicado: (2019)

The evolving Lebanese drug crisis: Trends in drug availability and affordability for common outpatient diseases from 2019 to 2023
por: Jaber Chehayeb, Rachel, et al.
Publicado: (2023)

Discovering drug–drug interactions: a text-mining and reasoning approach based on properties of drug metabolism
por: Tari, Luis, et al.
Publicado: (2010)

Augmented Intelligence for Clinical Discovery in Hypertensive Disorders of Pregnancy Using Outlier Analysis
por: Janoudi, Ghayath, et al.
Publicado: (2023)

Secondary Surgery in Facial Feminization: Reasons and Recommendations
por: Rochlin, Danielle, et al.
Publicado: (2022)

Patient Experiences of Primary Care by Visit Mode and Visit Reason During the COVID-19 Pandemic
por: Courtemanche, James, et al.
Publicado: (2022)

Identifying Novel Drug Indications through Automated Reasoning
por: Tari, Luis, et al.
Publicado: (2012)

Biosimilar Drugs: What Would Be a Reasonable Extrapolation?
por: Gifoni, Markus A.C., et al.
Publicado: (2017)

Drug resistance in intestinal tuberculosis: A reason to worry?
por: Sonambekar, Ajinkya, et al.
Publicado: (2017)

Lipoprotein Drug Delivery Vehicles for Cancer: Rationale and Reason
por: Chaudhary, Jaideep, et al.
Publicado: (2019)

Drug-induced haemolysis: another reason to be cautious with nitrofurantoin
por: Bhatt, Chaitanya, et al.
Publicado: (2023)

High Override Rate for Opioid Drug-allergy Interaction Alerts: Current Trends and Recommendations for Future
por: Topaz, Maxim, et al.
Publicado: (2015)

Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study
por: Kromer, Christian, et al.
Publicado: (2019)

Drug2ways: Reasoning over causal paths in biological networks for drug discovery
por: Rivas-Barragan, Daniel, et al.
Publicado: (2020)

Editorial: Recent trends and spotlight on nucleotide-based drugs: novel targets, their design, delivery, and clinical potential
por: Chander, Subhash, et al.
Publicado: (2023)

High performance in silico virtual drug screening on many-core processors
por: McIntosh-Smith, Simon, et al.
Publicado: (2015)

Reasoning in physics: the part of common sense
por: Viennot, L
Publicado: (2001)

Antibacterial Activity of Thymus Syriacus Boiss Essential Oil and Its Components against Some Syrian Gram-Negative Bacteria Isolates
por: Al-Mariri, Ayman, et al.
Publicado: (2013)

Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada
por: Nagase, Fernanda Naomi Inagaki, et al.
Publicado: (2019)

Reasons for unfulfilled breeding and transfer recommendations in zoos and aquariums
por: Gray, Steven M., et al.
Publicado: (2021)

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans
por: Salek, Sam, et al.
Publicado: (2019)

Reasons for illicit drug use in people with schizophrenia: Qualitative study
por: Asher, Carolyn J, et al.
Publicado: (2010)

Reasons for the Underutilization of Generic Drugs by US Ophthalmologists: A Survey
por: Dietze, Jamie, et al.
Publicado: (2020)

A systematic review of moral reasons on orphan drug reimbursement
por: Zimmermann, Bettina M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_stbvum6p1dof9gmr7gslia8iuc